BBP vs. VEMY
BBP (Virtus LifeSci Biotech Products ETF) and VEMY (Virtus Stone Harbor Emerging Markets High Yield Bond ETF) are both exchange-traded funds - BBP is a Health & Biotech Equities fund tracking the LifeSci Biotechnology Products Index, while VEMY is a Emerging Markets Bonds fund actively managed by Virtus. BBP is passively managed, while VEMY is actively managed. Over the past 3 years, BBP returned 20.67%/yr vs 14.01%/yr for VEMY. Their 0.37 correlation means their historical movements had little consistent relationship. BBP charges 0.79%/yr vs 0.58%/yr for VEMY.
Performance
BBP vs. VEMY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, BBP achieves a 17.95% return, which is significantly higher than VEMY's 6.07% return.
BBP
- 1D
- 0.42%
- 1M
- -4.86%
- 6M
- 13.89%
- YTD
- 17.95%
- 1Y
- 51.96%
- 3Y*
- 20.67%
- 5Y*
- 12.86%
- 10Y*
- 11.61%
- ALL TIME*
- 12.18%
VEMY
- 1D
- 0.40%
- 1M
- -0.46%
- 6M
- 3.41%
- YTD
- 6.07%
- 1Y
- 13.28%
- 3Y*
- 14.01%
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- 13.11%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $934.12K | $1.05M | $1.02M | |
| $924.57K | $860.95K | $887.68K |
BBP vs. VEMY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
BBP Virtus LifeSci Biotech Products ETF | 17.95% | 33.15% | 3.32% | 17.88% | -1.10% |
VEMY Virtus Stone Harbor Emerging Markets High Yield Bond ETF | 6.07% | 15.27% | 13.48% | 14.45% | -1.43% |
Correlation
The correlation between BBP and VEMY is 0.38, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.38 |
Correlation (3Y) Balances recent behavior with more history. | 0.40 |
Correlation (All Time) Calculated using the full available price history since Dec 13, 2022 | 0.37 |
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BBP vs. VEMY — Risk / Return Rank
BBP
VEMY
BBP vs. VEMY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Virtus LifeSci Biotech Products ETF (BBP) and Virtus Stone Harbor Emerging Markets High Yield Bond ETF (VEMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BBP | VEMY | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.04 | ||
| Sortino ratioReturn per unit of downside risk | -0.42 | ||
| Omega ratioGain probability vs. loss probability | 1.35 | 1.44 | -0.09 |
| Calmar ratioReturn relative to maximum drawdown | 5.55 | 3.33 | +2.22 |
| Martin ratioReturn relative to average drawdown | 15.50 | 15.31 | +0.19 |
Loading charts...
Drawdowns
BBP vs. VEMY - Drawdown Comparison
The maximum BBP drawdown since its inception was -44.32%, which is greater than VEMY's maximum drawdown of -8.77%. Use the drawdown chart below to compare losses from any high point for BBP and VEMY.
Loading charts...
Drawdown Indicators
| BBP | VEMY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -44.32% | -8.77% | -35.55% |
Max Drawdown (1Y)Largest decline over 1 year | -9.41% | -4.00% | -5.41% |
Max Drawdown (3Y)Largest decline over 3 years | -26.09% | -6.57% | -19.52% |
Max Drawdown (5Y)Largest decline over 5 years | -37.77% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -44.32% | — | — |
Current DrawdownCurrent decline from peak | -9.03% | -0.68% | -8.35% |
Average DrawdownAverage peak-to-trough decline | -11.90% | -1.27% | -10.63% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.36% | 0.87% | +2.49% |
Volatility
BBP vs. VEMY - Volatility Comparison
Virtus LifeSci Biotech Products ETF (BBP) has a higher volatility of 7.29% compared to Virtus Stone Harbor Emerging Markets High Yield Bond ETF (VEMY) at 1.19%. This indicates that BBP's price experiences larger fluctuations and is considered to be riskier than VEMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BBP | VEMY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 7.29% | 1.19% | +6.10% |
Volatility (6M)Calculated over the trailing 6-month period | 19.11% | 4.54% | +14.57% |
Volatility (1Y)Calculated over the trailing 1-year period | 24.10% | 6.04% | +18.06% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 26.43% | 7.52% | +18.91% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 27.35% | 7.52% | +19.83% |
BBP vs. VEMY - Expense Ratio Comparison
BBP has a 0.79% expense ratio, which is higher than VEMY's 0.58% expense ratio.
Dividends
BBP vs. VEMY - Dividend Comparison
BBP has not paid dividends to shareholders, while VEMY's dividend yield for the trailing twelve months is around 8.09%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BBP Virtus LifeSci Biotech Products ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.18% | 0.00% | 1.29% |
VEMY Virtus Stone Harbor Emerging Markets High Yield Bond ETF | 8.09% | 8.89% | 10.28% | 9.55% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Frequently Asked Questions
BBP and VEMY have a correlation of 0.38, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
BBP has higher volatility (7.29%) compared to VEMY (1.19%). In terms of maximum drawdown, BBP dropped -44.32% vs VEMY's -8.77%.
On 3-year performance, BBP leads with 20.67% vs 14.01% for VEMY. On fees, VEMY is cheaper at 0.58% per year. On volatility, VEMY has been the lower-risk option at 1.19%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 3-year period, BBP has performed better with a 20.67% return vs 14.01%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
VEMY is cheaper with a 0.58% expense ratio, compared with 0.79% for BBP.
VEMY has the higher dividend yield at 8.09%, compared with 0.00% for BBP.
BBP is categorized as Health & Biotech Equities, while VEMY is Emerging Markets Bonds. Their fees differ too: 0.79% for BBP and 0.58% for VEMY.
VEMY currently has the higher Sharpe Ratio (2.21 vs 2.17), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for BBP and VEMY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer